Experience of using «NefroBest-N» for rehabilitation of patients undergoing radical laparoscopic cystectomy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the efficacy and safety of NefroBest-N in patients undergoing to the radical cystectomy with neobladder formation.

Materials and methods. A total of 60 patients with invasive bladder cancer aged 56 to 75 years, treated at A.I. Burnazyan SRC FMBC and at the M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care in 2022, were included in randomized multicenter parallel group study. All patients underwent radical cystectomy with a formation of Studer neobladder. The main group included those who received the drug NefroBest-N, 1 capsule 2 times a day for 90 days. In the control group, only symptomatic therapy according to current standards was administered. The study consisted of a screening period of up to 4 days (Visit 1) and a period of 90+2 days to evaluate the efficiency of therapy, including 3 visits: day 14 (Visit 2), 30+2 days (Visit 3) and 90+2 days (Visit 4). Laboratory examination and imaging studies included biochemistry panel (urea, creatinine, K, Na, CRP), urinalysis (presence of mucus, leukocytes), urine culture (bacteriuria), physical examination, renal and neobladder ultrasound with determination of postvoid residual volume. In addition, evaluation of the quality of life was also performed.

Results. Evaluation of efficacy and safety of NefroBest-N was carried out. Administration of NefroBest-N resulted in a more rapid improvement of urinalysis, including a significant decrease in severity of leukocyturia and amount of mucus. In addition, degree of bacteriuria was reduced according to the urine culture. The quality of life was also improved.

Conclusion. NefroBest-N has a favorable efficacy and safety profile. According to our experience, NefroBest-N significantly reduces recovery time and improves the quality of life of patients who have undergone radical cystectomy with a neobladder formation.

Full Text

Restricted Access

About the authors

F. G. Kolpacinidi

A.I. Burnazyan SRC FMBC, FMBA of Russia

Author for correspondence.
Email: Fedor_dr@mail.ru

urologist, Center of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia

Russian Federation, Moscow

V. P. Sergeev

A.I. Burnazyan SRC FMBC, FMBA of Russia

Email: garivas@yandex.ru

urologist, Head of the Department of Oncouology of A.I. Burnazyan SRC FMBC, FMBA of Russia

Russian Federation, Moscow

P. S. Kyzlasov

A.I. Burnazyan SRC FMBC, FMBA of Russia

Email: dr.kyzlasov@mail.ru

Dr. Sc., Head of the Center of Urology and Andrology FMBC them. A. I. Burnazyan FMBA of Russia, Head of the Center of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia, Chief urologist of the FMBA of Russia

Russian Federation, Moscow

E. V. Volokitin

M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care

Email: evgvolokitin82@mail.ru

urologist, Head of the Urology division, M.A. Podgorbunsky Kuzbass Сlinical Hospital of Emergency Medical Care

Russian Federation, Kemerovo

G. G. Abuev

A.I. Burnazyan SRC FMBC, FMBA of Russia

Email: abuev.urology@gmail.com

urologist, PhD-student of department of urology and andrology FMBC them. A. I. Burnazyan FMBA of Russia

Russian Federation, Moscow

A. T. Mustafaev

A.I. Burnazyan SRC FMBC, FMBA of Russia

Email: dr.mustafayevat@gmail.com

urologist, Center of Urology and Andrology FMBC them. A. I. Burnazyan FMBA of Russia

Russian Federation, Moscow

A. A. Korobov

A.I. Burnazyan SRC FMBC, FMBA of Russia

Email: corobov97@yandex.ru

urologist, Ph.D. student at the Department of Urology and Andrology of A.I. Burnazyan, FMBA of Russia

Russian Federation, Moscow

References

  1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020;70(4):313. PMID: 30207593.
  2. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26. PMID: 23485231.
  3. Malignant neoplasms in Russia in 2019 (morbidity and mortality) Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. M.: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution «NMIC of Radiology» of the Ministry of Health of Russia. 2020. fig. 252 p. Russian (Злокачественные новообразования в России в 2019 году (заболеваемость и смертность) Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2020. илл. 252 с.) ISBN 978-5-85502-260-5
  4. Lenis A.T., Lec P.M., Chamie K., Mshs M.D. Bladder Cancer: A Review. JAMA. 2020;324(19):1980−1991. doi: 10.1001/jama.2020.17598. PMID: 33201207.
  5. Shkodkin S.V., Idashkin Yu.B. The choice of the method of urine derivation after radical cystectomy in the group of high anesthetic risk. Oncourology. 2020;16(1):90–98. Russian (Шкодкин С.В., Идашкин Ю.Б. Выбор метода деривации мочи после радикальной цистэктомии в группе высокого анестезиологического риска. Онкоурология. 2020;16(1):90–98). https://doi.org/10.17650/1726-9776-2020-16-1-90-98
  6. Clark P.E., Stein J.P., Groshen S.G., Cai J., Miranda G., Lieskovsky G., Skinner D.G. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005;104(1):36−43. doi: 10.1002/cncr.21126. PMID: 15912515.
  7. World Health Organization (WHO) Consensus Conference on Bladder Cancer; Hautmann R.E., Abol-Enein H., Hafez K., Haro I., Mansson W., Mills R.D., Montie J.D., Sagalowsky A.I., Stein J.P., Stenzl A., Studer U.E., Volkmer B.G. Urinary diversion. Urology. 2007;69(1 Suppl):17–49. doi: 10.1016/j.urology.2006.05.058. PMID: 17280907.
  8. Proskokov A.A., Darenkov S.P., Agabekyan A.A., Trofimchuk A.D. Current trends in the choice of urine derivation method in patients after radical cystectomy for invasive bladder cancer. Urology. 2019;6:120–124. Russian (Проскоков А.А., Даренков С.П., Агабекян А.А., Трофимчук А.Д. Современные тенденции в выборе метода деривации мочи у пациентов после радикальной цистэктомии по поводу инвазивного рака мочевого пузыря. Урология. 2019;6:120–124). doi: 10.18565/urology.2019.6.120-124.
  9. Spitsyn I.M., Perepechai V.A., Kogan M.I. Heterotopic continental forms of urine derivation. Bulletin of Urology. 2017;5(1):64–70. Russian (Спи- цын И.М., Перепечай В.А., Коган М.И. Гетеротопические континентные формы деривации мочи. Вестник урологии. 2017;5(1):64–70). https://doi.org/10.21886/2308-6424-2017-5-1-64-70
  10. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–1587. doi: 10.1200/JCO.1998.16.4.1582. PMID: 9552069.
  11. Semenyakin I., Vasilchenko M., Tarasenko V., Zelenin D. The choice of the method of urine removal after cystectomy. Bulletin of Experimental and Clinical Surgery. 2013;6(3):343–348. Russian (Семенякин И., Васильченко М., Тарасенко В., Зеленин Д. Выбор метода отведения мочи после цистэктомии. Вестник экспериментальной и клинической хирургии. 2013;6(3):343–348). doi: 10.18499/2070-478X-2013- 6-3-343-348
  12. Hautmann R.E., de Petriconi R.C., Volkmer B.G. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–994. doi: 10.1016/j.juro.2010.05.037. PMID: 20643429.
  13. Yang L.S., Shan B.L., Shan L.L., Chin P., Murray S., Ahmadi N., Saxena A. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016;25(3):281–297. doi: 10.1016/j.suronc.2016.05.027.
  14. Vasiliev O.N., Perepechai V.A., Ryzhkin A.V. Early and late postoperative complications after radical cystectomy for bladder cancer. Bulletin of Urology. 2019;7(2):24–50. Russian (Васильев О.Н., Перепечай В.А., Рыжкин А.В. Ранние и поздние послеоперационные осложнения после радикальной цистэктомии при раке мочевого пузыря. Вестник урологии. 2019;7(2):24–50). https://doi.org/10.21886/2308-6424-2019-7-2-24-50

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Comparison of the dynamics of the CRP indicator between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (41KB)
Indexing metadata
3. Fig. 2. Comparison of the dynamics of the urea indicator between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (38KB)
Indexing metadata
4. Fig. 3. Comparison of the dynamics of creatinine between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (49KB)
Indexing metadata
5. Fig. 4. Comparison of the dynamics of quality of life index scores between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (39KB)
Indexing metadata
6. Fig. 5. Comparison of the dynamics of the amount of mucus in urine analysis (in points) between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (48KB)
Indexing metadata
7. Fig. 6. Comparison of the dynamics of the degree of bacteriuria according to bacteriological examination of urine (in points) between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (40KB)
Indexing metadata
8. Fig. 7. Comparison of leukocyturia dynamics between groups during visits, p<0.05 (significant difference between groups on the 4th visit)

Download (38KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies